BRIEF RESEARCH REPORT article
Front. Oncol.
Sec. Cardio-Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1612758
This article is part of the Research TopicTargets in Cardio-Oncology: Drug Effects and Mechanisms of ActionView all 18 articles
Electrocardiographic Changes in QTc Interval and Other Parameters Associated with Osimertinib Therapy
Provisionally accepted
- 1Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China
- 2Emergency Critical Care Center, Beijing Anzhen Hopital, Capital Medical University, Beijing, China
- 3Department of Pharmacy, China-Japan Union Hospital, Jilin University, Changchun, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Osimertinib, a third-generation EGFR-TKI, is approved for the first-line treatment of EGFR-mutated advanced NSCLC and for T790M-positive NSCLC after progression on previous EGFR-TKI therapy. Osimertinib is associated with cardiotoxicity, including severe QT interval prolongation, which necessitates detailed evaluation due to its increasing use.This retrospective, single-center study conducted at Jilin University China-Japan Union Hospital evaluated electrocardiographic changes with EGFR-mutated NSCLC treated with osimertinib. The study consecutively included 102 patients diagnosed with NSCLC at the China-Japan Union Hospital of Jilin University from August 1, 2019, to December 31, 2022. Among them, 41 patients who had both pre-and post-treatment ECG records while receiving osimertinib (80 mg daily) were analyzed. ECG parameters such as heart rate, PR interval, QRS duration, QRS axis, and QT intervals were manually calculated and analyzed.The study population had a mean age of 68.56 ± 8.73 years, comprising 46.34% males. Significant changes were observed in the QTc Bazett interval (P < 0.0001), QTc Fridericia interval (P = 0.0002) and QRS axis (P = 0.0387) post-treatment. QT interval prolongation was significant (McNemar test P = 0.0039), with both QTc Bazett and QTc Fridericia intervals showing notable prolongation. However, the changes in heart rate, PR interval, and QRS duration were not statistically significant.This study comprehensively investigates the electrocardiographic changes before and after osimertinib treatment in patients with EGFR-mutated NSCLC. The significant prolongation of QTc intervals underscores the need for rigorous ECG monitoring to mitigate potential cardiotoxicity.
Keywords: Osimertinib, QTc interval, Electrocardiographic changes, cardiotoxicity, Cardio-oncology
Received: 16 Apr 2025; Accepted: 02 Jun 2025.
Copyright: © 2025 Pan, Peng, Jiang, Yang, Du and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Beibei Du, Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China
Yuquan He, Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.